

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-18. **(Cancelled)**

19. **(Currently amended)** A method of treating CLL comprising:
determining whether OX-2/CD200 is upregulated in a human subject afflicted with CLL; and
administering to those subjects in which OX-2/CD200 is upregulated ~~a polypeptide an antibody or antigen-binding fragment thereof that binds to human OX-2/CD200 or an OX-2/CD200 receptor, the polypeptide said antibody or antigen-binding fragment thereof being administered in an amount effective to inhibit the an immune-suppressing effect of OX-2/CD200 in said subject.~~

20. **(Cancelled)**

21. **(Currently amended)** A method as in claim 19, wherein the step of administering a ~~polypeptide antibody comprises administering to the subject is~~ a monoclonal antibody that binds to OX-2/CD200.

22-42. **(Cancelled)**

43. **(Currently Amended)** A method as in claim 19, wherein the step of administering a ~~polypeptide comprises administering an antibody or antigen-binding fragment thereof containing comprises a light chain CDR1 region having a comprising the sequence selected from the group consisting of set forth in SEQ ID NOS: 5, 12 and 13 SEQ ID NO: 12; a light chain CDR2 comprising the sequence set forth in SEQ ID NO: 23; a light chain CDR3 comprising the sequence set forth in SEQ ID NO: 37; a heavy chain CDR1 comprising the sequence set forth in SEQ ID NO:~~

55; a heavy chain CDR2 comprising the sequence set forth in SEQ ID NO: 74; and a heavy chain CDR3 comprising the sequence set forth in SEQ ID NO: 93.

44. **(Withdrawn – currently amended)** A method as in claim 19, wherein the step of administering a polypeptide comprises administering an antibody or antigen-binding fragment thereof containing comprises a light chain CDR2 CDR1 region having a comprising the sequence selected from the group consisting of set forth in SEQ ID NOS: 21 and 23 SEQ ID NO: 5; a light chain CDR2 comprising the sequence set forth in SEQ ID NO: 21; a light chain CDR3 comprising the sequence set forth in SEQ ID NO: 29; a heavy chain CDR1 comprising the sequence set forth in SEQ ID NO: 50; a heavy chain CDR2 comprising the sequence set forth in SEQ ID NO: 69; and a heavy chain CDR3 comprising the sequence set forth in SEQ ID NO: 88.

45. **(Withdrawn - currently amended)** A method as in claim 19, wherein the step of administering a polypeptide comprises administering an antibody or antigen-binding fragment thereof containing comprises a light chain CDR3 region CDR1 having a comprising the sequence selected from the group consisting of set forth in SEQ ID NO: 13; SEQ ID NOS: 29, 37 and 38 a light chain CDR2 comprising the sequence set forth in SEQ ID NO: 23; a light chain CDR3 comprising the sequence set forth in SEQ ID NO: 38; a heavy chain CDR1 comprising the sequence set forth in SEQ ID NO: 56; a heavy chain CDR2 comprising the sequence set forth in SEQ ID NO: 75; and a heavy chain CDR3 comprising the sequence set forth in SEQ ID NO: 94.

46-51. **(Canceled)**

52. **(Currently amended)** A method as in claim 2-19, wherein the antibody is selected from the group consisting of humanized antibodies, chimeric antibodies, Fvs, scFvs, Fab's and F(ab')₂s F(ab')₂s.

53. **(Currently amended)** A method as in claim 8 43, wherein the antibody is selected from the group consisting of humanized antibodies, chimeric antibodies, Fvs, scFvs, Fab's and F(ab')2s F(ab')2s.

54. **(Withdrawn - currently amended)** A method as in claim 14 44 wherein the antibody is selected from the group consisting of humanized antibodies, chimeric antibodies, Fvs, scFvs, Fab's and F(ab')2s F(ab')2s.

55. **(Withdrawn - currently amended)** A method as in claim 20 45 wherein the antibody is selected from the group consisting of humanized antibodies, chimeric antibodies, Fvs, scFvs, Fab's and F(ab')2s F(ab')2s.

56-70. (Not Entered)

71. **(New)** A method for determining whether a human subject is afflicted with CLL, comprising determining whether OX-2/CD200 is upregulated in said subject.

72. **(New)** The method of claim 71, wherein upregulation of OX-2/CD200 in said subject is determined using an antibody, or antigen binding fragment thereof, that specifically binds to OX-2/CD200.

73. **(New)** The method of claim 72, wherein the antibody, or antigen-binding fragment thereof, is selected from the group consisting of a monoclonal antibody, a humanized antibody, a chimeric antibody, Fv, scFv, Fab' and F(ab')2.

74. **(New)** The method of claim 72, wherein the antibody, or antigen-binding fragment thereof, is humanized.

75. (New) The method of claim 72, wherein the antibody, or antigen-binding fragment thereof, comprises a light chain CDR1 comprising the sequence set forth in SEQ ID NO: 12, a light chain CDR2 comprising the sequence set forth in SEQ ID NO: 23, a light chain CDR3 comprising the sequence set forth in SEQ ID NO: 37, a heavy chain CDR1 comprising the sequence set forth in SEQ ID NO: 55, a heavy chain CDR2 comprising the sequence set forth in SEQ ID NO: 74, and a heavy chain CDR3 comprising the sequence set forth in SEQ ID NO: 93.

76. (New) The method of claim 72, wherein the antibody, or antigen-binding fragment thereof, comprises a light chain CDR1 comprising the sequence set forth in SEQ ID NO: 5; a light chain CDR2 comprising the sequence set forth in SEQ ID NO: 21; a light chain CDR3 comprising the sequence set forth in SEQ ID NO: 29; a heavy chain CDR1 comprising the sequence set forth in SEQ ID NO: 50; a heavy chain CDR2 comprising the sequence set forth in SEQ ID NO: 69; and a heavy chain CDR3 comprising the sequence set forth in SEQ ID NO: 88.

77. (New) The method of claim 72, wherein the antibody, or antigen-binding fragment thereof, comprises a light chain CDR1 comprising the sequence set forth in SEQ ID NO: 13; a light chain CDR2 comprising the sequence set forth in SEQ ID NO: 23; a light chain CDR3 comprising the sequence set forth in SEQ ID NO: 38; a heavy chain CDR1 comprising the sequence set forth in SEQ ID NO: 56; a heavy chain CDR2 comprising the sequence set forth in SEQ ID NO: 75; and a heavy chain CDR3 comprising the sequence set forth in SEQ ID NO: 94.

78. (New) The method of claim 71, wherein the cancer is melanoma.